BioCentury | Jul 11, 2016
Finance

Shedding red

...I trial to treat chronic HCV infection Revance Therapeutics Inc. (NASDAQ:RVNC) Revance discontinues development of daxibotulinumtoxinA Topical Gel...
BioCentury | Jun 20, 2016
Clinical News

DaxibotulinumtoxinA Topical Gel: Phase III data

...II trial to treat cervical dystonia. Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: DaxibotulinumtoxinA Topical Gel (RT001, RTT150...
BioCentury | Jun 14, 2016
Clinical News

Revance's crow's feet treatment fails Phase III

...Therapeutics Inc. (NASDAQ:RVNC) fell $4.44 (24%) to $13.91 in early after-hours trading Monday after its daxibotulinumtoxinA Topical Gel...
BioCentury | Jan 18, 2016
Clinical News

RT001: Interim Phase II data

...II trial of RT001 to treat hyperhidrosis. Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RT001, RTT150...
BioCentury | Oct 5, 2015
Clinical News

RT001: Phase III started

...with moderate to severe lateral canthal lines. Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RT001, RTT150...
BioCentury | Sep 21, 2015
Clinical News

RTT150: Phase II started

...of topical RTT150 in about 60 adult patients. Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RTT150...
Items per page:
1 - 6 of 6